SUBSCRIBE
SUBSCRIBE

Clinical research

Drug Development
AstraZeneca’s Farxiga Shows ‘Overwhelming Efficacy’ in Phase III CKD Trial
AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease.
March 30, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: March 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
March 30, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Martin Good / Shutterstock
Drug Development
WHO Initiates a Clinical Trial for Four Drugs in Fight Against COVID-19
The World Health Organization is launching a clinical trial in Norway and Spain to assess four of the most promising drugs in the fight against COVID-19, the disease caused by the novel coronavirus that has spread across the globe.
March 27, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Clinical Catch-Up: March 23-27
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
March 27, 2020
 · 
8 min read
 · 
Mark Terry
Drug Development
BMS, Merck and Pfizer Join List of Companies Pausing Some Clinical Trials During Pandemic
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
March 27, 2020
 · 
3 min read
 · 
Alex Keown
Pictured: Atopic dermatitis patient scratches thei
Drug Development
Medimetriks and Otsuka’s Difamilast Hits Mark in Atopic Dermatitis Trials
Difamilast is a novel atopic dermatitis compound discovered by Otsuka.
March 27, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 27: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
March 27, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 26: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
March 26, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 25: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
March 25, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 24: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
March 24, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 30, 2026
 · 
7 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
January 29, 2026
 · 
5 min read
Press Releases
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
January 29, 2026
 · 
2 min read
Press Releases
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
 · 
4 min read
Press Releases
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
 · 
7 min read
Press Releases
Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
January 29, 2026
 · 
1 min read
Press Releases
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
January 29, 2026
 · 
6 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
OMEICOS Therapeutics Announces Positive Phase 2 Study Outcome Demonstrating OMT-28’s Potential in Primary Mitochondrial Diseases (PMD)
January 29, 2026
 · 
5 min read
Press Releases
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
January 29, 2026
 · 
4 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
January 29, 2026
 · 
4 min read
Press Releases
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
January 29, 2026
 · 
8 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
January 29, 2026
 · 
3 min read
Press Releases
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
January 29, 2026
 · 
3 min read
Press Releases
nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B
January 29, 2026
 · 
2 min read
Load More